Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NTX-472
- Development stage
- Preclinical
- Lead developer
- MediciTx
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
NTX-472 is a preclinical, trispecific, mRNA-based immunotherapy developed for the treatment of B cell lymphoma. It encodes a multispecific antibody that simultaneously targets CD20, CD19, and CD47 antigens on B cells. The therapy is delivered as an mRNA nanoparticle formulation that instructs cells to produce the engineered protein in vivo. By engaging these three targets at once, NTX-472 aims to enhance tumor cell killing and overcome resistance mechanisms seen with monospecific antibodies (such as antigen downregulation). Preclinical studies have demonstrated rapid depletion of B cells without detectable binding to red blood cells, suggesting a favorable safety profile compared to other anti-CD47 therapies[2][3][4][6][7].
- Brand names
- NTX-472NTX472NTX 472
- Other names
- M-23032M23032M 23032
02
Targets
CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)CD47 (Cluster of Differentiation 47)SIRPA (Signal-regulatory protein alpha)
Beyond the preview
Go deeper on NTX-472.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NTX-472.